The latest version of the Advisory Statement for Haematologists on Suspected Vaccine Induced Prothrombotic Immune Thrombocytopenia (VIPIT)/Vaccine induced immune thrombotic thrombocytopenia VITT), developed by the THANZ Vaccine Thrombocytopenia Working Group, is available here. This statement was first published on 1st April 2021 and last updated on 10th Jan 2022. As this is an emerging area of practice, please continue to check back for updates and to monitor the literature for publications.
- SUSPECTED VITT BLOOD TEST REQUEST FORM
Suspected Vaccine-induced Thrombotic Thrombocytopenia (VITT, previously VIPIT): Blood test request form (updated 17 June)
- CONFIRMED VITT FOLLOW UP BLOOD TEST REQUEST FORM
Confirmed Vaccine-induced Thrombotic Thrombocytopenia (VITT): Follow up Blood test request form (to be published 22 Feb 2022)
- Multidisciplinary VITT Guideline for Doctors (updated 7th July)
A THANZ and HSANZ joint statement (25th March 2021) regarding the potential risk of thrombotic/bleeding events after COVID‐19 vaccination is available here.
ATAGI statement (8th April) on the AstraZeneca COVID-19 vaccine in response to new vaccine safety concerns for the general public is available here
ATAGI Statement (25th March 2021) for health care providers on suitability of COVID-19 vaccination in people with history of clotting conditions is available here
